In summary, using genetically modified mouse and cell models we demonstrated that PTPN13 acts as a tumor suppressor in breast cancer and that it inhibits tumor aggressiveness through a SNAIL- and ZEB-independent MET-like transition, cautioning against the use of PTPN13 as a therapeutic target to increase apoptosis during cancer therapies 59,60. This evidence concerns the gene ZEB1 and breast carcinoma.